About UHN Research

Scientists

Resources and Services

Institutional Authorization

UHN Collaborative Centre for Drug Discovery

About Us

The Collaborative Centre for Drug Discovery (C2D2) at UHN comprises two complementary groups: the Structural Genomics Consortium Toronto (SGC-Toronto) and UHN Therapeutics. C2D2’s mandate is to identify novel discoveries in disease biology and turn them into tractable drug targets through collaboration with teams at UHN and the broader Toronto research ecosystem.

C2D2 specializes in the development of new small molecules that modulate drug targets to answer complex questions surrounding disease mechanisms and strategies for intervention. Additionally, C2D2 aims to empower novel capabilities and strategic partnerships for advancing the development of new therapeutics in conjunction with the Commercialization at UHN team.

Drug Discovery framework

Our operating framework involves a synergistic collaboration between SGC Toronto and UHN Therapeutics. Novel drug targets identified at UHN and the broader research ecosystem will be evaluated with diligence by both groups. Proposals and plans will then be generated in accordance with the specific needs of the project/target.

Cheryl Arrowsmith
Cheryl Arrowsmith, Co-Chair
Dr. Cheryl Arrowsmith is a Senior Scientist at UHN’s Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto.
Mark Reed
Mark Reed, Co-Chair
Dr. Mark Reed is a Scientist at UHN’s Krembil Brain Institute (KBI), Assistant Professor in the Departments of Chemistry and Pharmacology & Toxicology at the University of Toronto, and the head of UHN Therapeutics at KBI.

Events

Click here to see upcoming and past events for the UHN Collaborative Centre for Drug Discovery.

Collaborate with Us!

We partner with investigators, clinicians, and innovators to translate bold ideas in disease biology into tractable drug discovery programs. By combining deep biological insight with integrated therapeutic development expertise, we work collaboratively to de-risk novel targets, accelerate early discovery, and enable new pathways toward patient impact. Our model is built on openness, scientific rigor, commercialization, and meaningful partnership—bringing together expertise across disciplines to advance high-quality, actionable discoveries.

How to Get Started

  • Connect with us: Reach out to therapeutics@uhn.ca about your targets.
  • Set up a meeting: To learn more about your target, challenges, research, and goals.
  • Due diligence: We will evaluate your target to determine the druggability of your target.
  • Collaborate: Together, we will formulate a drug discovery program tailored to your target and begin research based on your target needs.

SGC-Toronto

Website: https://www.thesgc.org/scientists/groups/toronto
Contact: thesgc.toronto@gmail.com

UHN Therapeutics

Website: Coming soon.
Contact: therapeutics@uhn.ca